Q-omics provides the consensus-scored CHIAP2 profile across patient tissues and cancer cell-line models. CHIAP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CHIAP2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, CHIAP2 RNA expression shows 7,002 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, LUSC, and LSCC as cancer lineages where CHIAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHIAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHIAP2 survival associations across molecular data types. CHIAP2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHIAP2 RNA expression–survival associations across cancer types. High CHIAP2 expression shows unfavorable associations in DLBC, MESO, KIRP, UVM and LIHC, but favorable associations in LUAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for CHIAP2 RNA expression.
This table summarizes CHIAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CHIAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHIAP2 shows lower tumor expression in LUSC and LUAD and higher tumor expression in THCA, COAD and KIRP. The LUSC box plot shows higher CHIAP2 RNA expression in normal versus tumor tissue (log2 FC = −4.145, t-test p < 0.001).
This table shows molecular features associated with CHIAP2 in patient tissues and cancer cell lines. In patient samples, CHIAP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHIAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
